Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer by Andrew J. Weickhardt, David K. Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J. Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y. Luk, John M. Mariadason

Get full text

K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines by Yvonne Yeung, David K. Lau, Fiona Chionh, Hoanh Tran, Janson W. T. Tse, Andrew J. Weickhardt, Mehrdad Nikfarjam, Andrew M. Scott, Niall C. Tebbutt, John M. Mariadason

Get full text

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer by Fiona Chionh, Val Gebski, Sheren J. Al-Obaidi, Jennifer K. Mooi, Maressa A. Bruhn, Chee K. Lee, Anderly C. Chüeh, David S. Williams, Andrew J. Weickhardt, Kate Wilson, Andrew M. Scott, John Simes, Jennifer E. Hardingham, Timothy J. Price, John M. Mariadason, Niall C. Tebbutt

Get full text

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets by David K. Lau, Dmitri Mouradov, Wiphawan Wasenang, Ian Y. Luk, Cameron M. Scott, David S. Williams, Yvonne H. Yeung, Temduang Limpaiboon, George F. Iatropoulos, Laura J. Jenkins, Camilla M. Reehorst, Fiona Chionh, Mehrdad Nikfarjam, Daniel Croagh, Amardeep S. Dhillon, Andrew J. Weickhardt, Toshihide Muramatsu, Yoshimasa Saito, Niall C. Tebbutt, Oliver M. Sieber, John M. Mariadason

Get full text